Detection of clindamycin susceptibility in macrolide resistant phenotypes of Staphylococcus aureus

Indian Journal of Medical Microbiology

Volumn 22, Issue 4, 2004, Pages 251-254

  Goyal, R ^a   Singh, N P ^a   Manchanda, V ^a   Mathur, M ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Clindamycin; Macrolide; MRSA; S.aureus

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; MACROLIDE; METICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; IN VITRO STUDY; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE;

EID: 6944226247     PISSN: 02550857     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0255-0857(21)02773-0     Document Type: Article

References (13)

1. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in Staphylococci. Clin Microbiol Rev 2002;15(3):430-438.
2. Johnson AP, Woodford N. Glycopeptide resistant Staphylococcus aureus. J Atimicrobial Chemotherapy 2002;50 621-623.
3. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis 2003;36:473-481.
4. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: Nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-492.
5. Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin resistant staphylococci? J Antimicrobial Chemotherapy l999; 44:581-582.
6. Gopal Rao G. Should clindamycin be used in treatment of patients with infections caused by erythromycin resistant staphylococci? J Antimicrobial Chemotherapy2000;45:715.
7. Drinkovie D, Fuller ER, Shore KP, Holland DJ, Rod Ellis Pegler. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrobial Chemotherapy 2001;48: 315-16.
8. Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarsitis. clinical relapse and level of resistance to clindamycin, lincomycin and erythromycin. Am J Med1976;60 419-25.
9. Kloos WE, Banerman TL. Staphylococcus and Micrococcus, In: Chapter 22 Manual of clinical Microbiology 7th ed. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, Eds. (ASM press, Washington DC) 1999:264-282.
10. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disc susceptibility tests: approved standards.NCCLS document, Wayne, Pa: NCCLS, 2000.
11. Seppala H, Nissinen A, Quan Yu, Huovinen P.Three different phenotypes of erythromycin resistant Streptococcus pyogenes in Finland. J Antimicrobial Chemotherapy 1993;32:885-891.
12. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standards.NCCLS document, Wayne, Pa.:NCCLS 2000.
13. Sanchez ML, Flint KK, Jones RN. Occurrence of macrolide-lincosamide streptogramin resistance among staphyloccocal clinical isolates at a university medical center: is false susceptibility to new macrolides and clindamycin a Contemporary clinical and in vitro testing problem? Diag Microbial infect Dis 1993;16:205-213.